Lanzhou Foci Pharmaceutical Hits Day Low at CNY 7.85 Amid Price Pressure

Lanzhou Foci Pharmaceutical Co., Ltd. experienced a significant decline in its stock performance today, with a drop of 7.03% as it reached an intraday low of CNY 7.85. This downturn is notable against the backdrop of the China Shanghai Composite, which fell by 3.63% on the same day. Over the past week, Lanzhou Foci has seen a cumulative decline of 11.38%, while its monthly performance mirrors this trend, also down by 11.38%. Year-to-date, the stock has decreased by 8.1%, contrasting with the broader market's decline of 3.92%. In the longer term, the company has faced challenges, with a three-year performance decline of 26.28% compared to a 16.02% increase in the Shanghai Composite. Key financial metrics indicate underlying issues, including a low Return on Capital Employed (ROCE) of 5.82%, suggesting limited profitability relative to capital employed. Additionally, the company's pre-tax profit has fallen significantly, and its debtors turnover ratio is at a low of 1.92 times. These factors contribute to the current market position of Lanzhou Foci Pharmaceutical Co., Ltd. within the pharmaceuticals and biotechnology sector.